Skip to main content
SpringerLink
Log in

Use of Imatinib Mesylate for Favorable Control of Hypercalcemia Mediated by Parathyroid Hormone-Related Protein in a Patient with Chronic Myelogenous Leukemia at Blast Phase

  • Case Report
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

The case of a 72-year-old woman with chronic myelogenous leukemia in blast phase (BP) with hypercalcemia is reported. Bone x-ray examination revealed multiple osteolytic lesions throughout the body. The serum level of parathyroid hormone-related protein (PTHrP) was elevated, and PTHrP messenger RNA (mRNA) was detectable in the peripheral blood mononuclear cells (PBMNC) at BP but was not detectable at chronic phase (CP). Treatment with conventional chemotherapy did not completely control either serum calcium level or serum PTHrP level. Treatment with imatinib mesylate (imatinib) alone rapidly normalized these parameters in parallel with a decrease in the number of blast cells. The treatment also maintained the patient in good condition for approximately 3 months, even though the number of blast cells, serum calcium level, serum PTHrP level, and PTHrP mRNA level increased at the terminal stage. Mutations of thep53, K-Ras, andBCR-ABL genes in PBMNC at BP were absent. A noteworthy feature in this patient was that PBMNC at BP but not at CP showed high Lyn mRNA expression. Taken together the findings showed that production of PTHrP by blast cells was favorably controlled by imatinib therapy alone. Imatinib may prolong survival time at BP even though the patients have the complication of PTHrP-mediated hypercalcemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Firkin F, Schneider H, Grill V. Parathyroid hormone-related protein in hypercalcemia associated with hematological malignancy.Leuk Lymphoma. 1998;29:499–506.

    Article  CAS  PubMed  Google Scholar 

  2. Hibi S, Funaki H, Ochiai-Kanai R, et al. Hypercalcemia in children presenting with acute lymphoblastic leukemia.Int J Hematol. 1997;66:353–357.

    Article  CAS  PubMed  Google Scholar 

  3. Kounami S, Yoshiyama M, Nakayama K, Hiramatsu C, Aoyagi N, Yoshikawa N. Severe hypercalcemia in a child with acute nonlym-phocytic leukemia: the role of parathyroid hormone-related protein and proinflammatory cytokines.Acta Haematol. 2004;112:160–163.

    Article  PubMed  Google Scholar 

  4. Vlasveld LT, Pauwels P, Ermens AA, Aarnoudse WH, Ooms HW, Haak HR. Parathyroid hormone-related protein (PTH-rP)-associated hypercalcemia in a patient with an atypical chronic lymphocytic leukemia.Neth J Med. 1999;54:21–26.

    Article  CAS  PubMed  Google Scholar 

  5. Shimonodan H, Nagayama J, Nagatoshi Y, et al. Acute lymphocytic leukemia in adolescence with multiple osteolytic lesions and hypercalcemia mediated by lymphoblast-producing parathyroid hormone-related peptide: a case report and review of the literature.Pediatr Blood Cancer. 2005;44:l-7.

    Google Scholar 

  6. Seymour JF, Grill V, Martin TJ, Lee N, Firkin F. Hypercalcemia in the blastic phase of chronic myeloid leukemia associated with elevated parathyroid hormone-related protein.Leukemia. 1993;7:1672–1675.

    PubMed  CAS  Google Scholar 

  7. Sasaki Y, Takahashi T, Tsuyuoka R, et al. Hypercalcemia mediated by parathyroid hormone-related protein in chronic myeloid leukemia.Am J Hematol. 1994;47:251–252.

    Article  CAS  PubMed  Google Scholar 

  8. Watanabe T, Kataoka T, Mizuta S, et al. Establishment and characterization of a novel cell line,TK-6, derived from T cell blast crisis of chronic myelogenous leukemia, with the secretion of parathyroid hormone-related protein.Leukemia. 1995;9:1926–1934.

    PubMed  CAS  Google Scholar 

  9. Kubonishi I, Asahi Y, Machida H, et al. PTHrP-mediated hypercalcaemia in a case of CML blast crisis.Br J Haematol. 1997;96:165–167.

    Article  CAS  PubMed  Google Scholar 

  10. Kwak HS, Sohn MH, Lim ST, Kwak JY, Yim CY. Technetium-99m MDP bone scintigraphic findings of hypercalcemia in accelerated phase of chronic myelogenous leukemia.J Korean Med Sci. 2000;15:598–600.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Kakihana K, Mizuchi D, Yamaguchi M, et al. Hypercalcemia mediated by parathyroid hormone-related protein in the blastic phase of chronic myelogenous leukemia [in Japanese].Rinsho Ketsueki. 2002;43:102–106.

    PubMed  Google Scholar 

  12. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia.Blood. 1984;63:789–799.

    PubMed  CAS  Google Scholar 

  13. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.J Natl Cancer Inst. 1998;90:850–858.

    Article  CAS  PubMed  Google Scholar 

  14. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia.N Engl J Med. 1986;314:1065–1069.

    Article  CAS  PubMed  Google Scholar 

  15. Li X, Drucker DJ. Parathyroid hormone-related peptide is a downstream target for ras and src activation.J Biol Chem. 1994;269:6263–6266.

    PubMed  CAS  Google Scholar 

  16. Hu Y, Liu Y, Pelletier S, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.Nat Genet. 2004;36:453–461.

    Article  CAS  PubMed  Google Scholar 

  17. Silver RT, Talpaz M, Sawyers CL, et al. Four year follow-up of phase II trials of patients with chronic myeloid leukemia (CML) treated with imatinib: patients with late chronic phase (CP), accelerated phase (AP), or myeloid blast crisis (BC). In: Program and abstracts of the 46th Annual Meeting of the American Society of Hematology; December 4–7, 2004; San Diego, California, USA. Abstract 23.

  18. Motokura T, Endo K, Kumaki K, Ogata E, Ikeda K. Neoplastic transformation of normal rat embryo fibroblasts by a mutated p53 and an activated ras oncogene induces parathyroid hormone-related peptide gene expression and causes hypercalcemia in nude mice.J Biol Chem. 1995;270:30857–30861.

    Article  CAS  PubMed  Google Scholar 

  19. Calabretta B, Perrotti D. The biology of CML blast crisis.Blood. 2004;103:4010–4022.

    Article  CAS  PubMed  Google Scholar 

  20. Dai Y, Rahmani M, Corey SJ, Dent P, Grant S. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.J Biol Chem. 2004;279:34227–34239.

    Article  CAS  PubMed  Google Scholar 

  21. Donato NJ,Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.Blood. 2003;101:690–698.

    Article  CAS  PubMed  Google Scholar 

  22. Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells.Nat Med. 2004;10:1187–1189.

    Article  CAS  PubMed  Google Scholar 

  23. Uchiumi F, Semba K, Yamanashi Y, et al. Characterization of the promoter region of the src family gene lyn and its trans activation by human T-cell leukemia virus type I-encoded p40tax.Mol Cell Biol. 1992;12:3784–3795.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Dittmer J, Pise-Masison CA, Clemens KE, Choi KS, Brady JN. Interaction of human T-cell lymphotropic virus type I Tax, Ets1, and Sp1 in transactivation of the PTHrP P2 promoter.J Biol Chem. 1997;272:4953–4958.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, 734-8553, Hiroshima, Japan

    Natsuki Miyoshi, Hideo Tanaka, Takuo Ito, Yuta Katayama, Hiromasa Niimi, Hideo Hyodo & Akiro Kimura

Authors
  1. Natsuki Miyoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hideo Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takuo Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yuta Katayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiromasa Niimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hideo Hyodo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Akiro Kimura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideo Tanaka.

About this article

Cite this article

Miyoshi, N., Tanaka, H., Ito, T. et al. Use of Imatinib Mesylate for Favorable Control of Hypercalcemia Mediated by Parathyroid Hormone-Related Protein in a Patient with Chronic Myelogenous Leukemia at Blast Phase. Int J Hematol 82, 333–337 (2005). https://doi.org/10.1532/IJH97.05063

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1532/IJH97.05063

Key words

Search

Navigation